Thursday, November 27, 2014 Last update: 3:33 PM - Covering Large & Obscure Tech Companies Since 1996

RegeneRx Chairman, Dr. Allan L. Goldstein, to Speak at Major Drug Industry Conference

Companies mentioned in this article: RegeneRx Biopharmaceuticals, Inc.

ROCKVILLE, Md. -- (BUSINESS WIRE) -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that Dr. Allan L. Goldstein, the Company’s chairman and chief scientific advisor and emeritus professor and chairman of biochemistry at The George Washington University School of Medicine, will be a plenary speaker at The Drug Discovery & Therapy World Congress 2014 in Boston, MA on Monday, June 16. Dr. Goldstein will open the meeting with a talk entitled, “Advances in Clinical Applications of Synthetic Thymosins in Treating Life-Threatening Diseases.”

About RegeneRx Biopharmaceuticals, Inc. (

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the EU, and has an extensive worldwide patent portfolio covering its products. The Company also has developed several peptides that it believes may be useful improving aging skin in the cosmeceutical field.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements made by Dr. Goldstein may involve speculation and uncertainties that may or may not prove to be accurate and may be materially different from any results implied by such forward-looking statements. Please view these and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

Copyright © Business Wire 2014

For RegeneRx:
Lori Smith, 301-208-9191